Table 3.
Microbiological Response–Microbiological Outcome | Gepotidacin 1500 mg |
Gepotidacin 3000 mg |
Total |
---|---|---|---|
Participants with urogenital NG at baseline | 30 | 39 | 69 |
Microbiological success | 29 (97) | 37 (95) | 66 (96) |
1-sided 95% confidence interval | (85.1, 100) | (84.7, 100) | (89.1, 100) |
1-sided P value | 0.011 | 0.009 | <0.001 |
Bacterial eradication | 29 (97) | 37 (95) | 66 (96) |
Microbiological failure | 1 (3) | 2 (5) | 3 (4) |
Bacterial persistence | 1 (3) | 2 (5) | 3 (4) |
Unable to determine | 0 | 0 | 0 |
Participants with pharyngeal NG at baseline | 0 | 2 | 2 |
Microbiological success | 0 | 1 (50) | 1 (50) |
Bacterial eradication | 0 | 1 (50) | 1 (50) |
Microbiological failure | 0 | 1 (50) | 1 (50) |
Bacterial persistence | 0 | 1 (50) | 1 (50) |
Participants with rectal NG at baseline | 1 | 2 | 3 |
Microbiological success | 1 (100) | 2 (100) | 3 (100) |
Bacterial eradication | 1 (100) | 2 (100) | 3 (100) |
Data are presented as number (%) unless otherwise indicated. If either the count of successes or the count of failures was ≤5, then exact tests were conducted to compute P values.
Abbreviation: NG, Neisseria gonorrhoeae.